Format
Sort by

Send to

Choose Destination

Search results

Items: 18

1.

CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers.

Sutton LM, Geradts J, Hamilton EP, Havlin KA, Kimmick GG, Marcom PK, Spector NL, Watson M, Rabin DU, Bruno TO, Noe A, Miller S, Subramaniam C, Layton S, Grichnik K.

J Natl Compr Canc Netw. 2015 Aug;13(8):1005-11.

PMID:
26285246
2.

Occult primary cancer clinical practice guidelines.

Ettinger DS, Arnoletti JP, Gockerman JP, Handorf C, Havlin KA, Jacobs CD, Javle M, Kvols L, Lenzi R, Rashid A, Rhoades CA, Ridge JA, Saltz L, Shulman LN, Sondak VK, Thompson JA, Twardowski P, Zhen W; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Mar;3(2):214-33. No abstract available.

PMID:
19817031
3.

Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.

Havlin KA, Ramirez MJ, Legler CM, Harris LN, Matulonis UA, Hohneker JA, Hayes DF, Winer EP.

Cancer Chemother Pharmacol. 1999;43(1):68-72.

PMID:
9923543
4.

Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.

Chu L, Sutton LM, Peterson BL, Havlin KA, Winer EP.

J Infus Chemother. 1996 Fall;6(4):211-6.

PMID:
9229318
5.

Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic study.

Havlin KA, Kuhn JG, Koeller J, Boldt DH, Craig JB, Brown TD, Weiss GR, Cagnola J, Phillips J, Harman G, et al.

Anticancer Drugs. 1995 Apr;6(2):229-36.

PMID:
7795272
6.

Etoposide in gastric cancer.

Macdonald JS, Havlin KA.

Semin Oncol. 1992 Dec;19(6 Suppl 13):59-62. Review.

PMID:
1492227
7.

A phase I clinical and pharmacokinetic trial of hepsulfam.

Ravdin PM, Havlin KA, Marshall MV, Brown TD, Koeller JM, Kuhn JG, Rodriguez G, Von Hoff DD.

Cancer Res. 1991 Dec 1;51(23 Pt 1):6268-72.

8.

Phase I evaluation of 773U82.HCl, a member of a new class of DNA intercalators.

Havlin KA, Kuhn JG, Craig JB, Weiss GR, Koeller J, Turner JN, Luther JS, Clark G, Bair KW, Wargin W, et al.

Anticancer Drugs. 1991 Aug;2(4):357-63.

PMID:
1797191
9.

Phase I clinical and pharmacokinetic trial of flavone acetic acid.

Havlin KA, Kuhn JG, Craig JB, Boldt DH, Weiss GR, Koeller J, Harman G, Schwartz R, Clark GN, Von Hoff DD.

J Natl Cancer Inst. 1991 Jan 16;83(2):124-8.

PMID:
1703237
10.

Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule.

Cobb PW, Havlin KA, Kuhn JG, Craig JB, Harman GS, Luther JS, Turner JN, Weiss GR, Tweedy DA, Koeller J, et al.

Sel Cancer Ther. 1991 Summer;7(2):85-91.

PMID:
1754731
11.

New anticancer agents.

Brown TD, Burris HA, Havlin KA, O'Rourke TJ, Rodriguez GI, Wall JG, Weiss GR.

Cancer Chemother Biol Response Modif. 1991;12:111-46. Review. No abstract available.

PMID:
1718374
12.

Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule.

Von Hoff DD, Kuhn JG, Havlin KA, Langevin AM, Brown TD, Weiss GR, Turner JN, Purvis J, Lucas VS, Bair KW, et al.

Cancer Res. 1990 Dec 1;50(23):7496-500.

13.

New anticancer agents.

Brown TD, Havlin KA, Koeller JM, Kuhn JG, O'Rourke TJ, Rodriguez GI, Weiss GR, Von Hoff DD.

Cancer Chemother Biol Response Modif. 1990;11:115-41. Review. No abstract available.

PMID:
2223393
14.

Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma.

Paulnock DM, Havlin KA, Storer BM, Spear GT, Sielaff KM, Borden EC.

J Interferon Res. 1989 Aug;9(4):457-73.

PMID:
2502586
15.

High-dose cisplatin for locally advanced or metastatic head and neck cancer. A phase II pilot study.

Havlin KA, Kuhn JG, Myers JW, Ozols RF, Mattox DE, Clark GM, von Hoff DD.

Cancer. 1989 Feb 1;63(3):423-7.

16.

Lack of interferon production by dipyridamole.

Havlin KA, Inglot AD, Willson JK, Borden EC, Grossberg S, Szulc B, Gladysz A, Groehlich B.

J Interferon Res. 1988 Apr;8(2):135-6.

PMID:
3379323
17.

Aminoglutethimide: theoretical considerations and clinical results in advanced prostate cancer.

Havlin KA, Trump DL.

Cancer Treat Res. 1988;39:83-96. Review. No abstract available.

PMID:
2908610
18.

New anticancer agents.

Weiss GR, Arteaga CL, Brown TD, Craig JB, Harman GS, Havlin KA, Koeller JM, Kuhn JG, Von Hoff DD.

Cancer Chemother Biol Response Modif. 1988;10:85-116. Review. No abstract available.

PMID:
2484323
Items per page

Supplemental Content

Loading ...
Write to the Help Desk